Desvenlafaxine Succinate: A New Serotonin and Norepinephrine Reuptake Inhibitor

@article{Deecher2006DesvenlafaxineSA,
  title={Desvenlafaxine Succinate: A New Serotonin and Norepinephrine Reuptake Inhibitor},
  author={Darlene C. Deecher and Chad E. Beyer and Grace H. Johnston and Jenifer A. Bray and S. Shah and Magid A Abou-Gharbia and Terrance H. Andree},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  year={2006},
  volume={318},
  pages={657 - 665}
}
  • D. Deecher, C. Beyer, T. Andree
  • Published 1 August 2006
  • Biology, Chemistry, Medicine
  • Journal of Pharmacology and Experimental Therapeutics
The purpose of this study was to characterize a new chemical entity, desvenlafaxine succinate (DVS). DVS is a novel salt form of the isolated major active metabolite of venlafaxine. Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or norepinephrine (NE) transporter (hNET) with Ki values for DVS of 40.2 ± 1.6 and 558.4 ± 121.6 nM, respectively. DVS showed weak binding affinity (62% inhibition at 100 μM) at the… 
View on ASPET
jpet.aspetjournals.org
208 Citations
Highly Influential Citations
14
Background Citations
72
Methods Citations
10
Results Citations
6

Figures and Tables from this paper

208 Citations

Citation Type

Citation Type

Desvenlafaxine Succinate Identifies Novel Antagonist Binding Determinants in the Human Norepinephrine Transporter
TLDR
It is documented that Val148 in hNET transmembrane domain 3 selectively disrupts NIS binding but not that of DVS, and these differences seem not to arise from preparation-specific perturbations of ligand intrinsic affinity or antagonist-specific surface trafficking but rather from protein conformational alterations that perturb the relationships between distinct hNET binding sites.
Pharmacological Characterization of Toludesvenlafaxine as a Triple Reuptake Inhibitor
TLDR
It is suggested that toludesvenlafaxine is a triple reuptake inhibitor with relatively fast-acting antidepressant-like activity and good therapeutic profile including improvement of anhedonia and sexual function.
Levomilnacipran (F2695), a norepinephrine-preferring SNRI: Profile in vitro and in models of depression and anxiety
The Effects of LPM570065, a Novel Triple Reuptake Inhibitor, on Extracellular Serotonin, Dopamine and Norepinephrine Levels in Rats
TLDR
Investigation of the effects of LPM570065 on extracellular 5-HT, DA and NE levels in the rat striatum after acute and chronic administration relative to desvenlafaxine suggests that LPM 570065 may have greater efficacy and/or a more rapid onset of antidepressant action than desVENlafAXine and also counterbalance the harmful effects of desvenLafaxines.
Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties
Pharmacokinetic and pharmacodynamic profiles of the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized Sprague–Dawley rats
In vitro and in vivo characterization of PA01, a novel promising triple reuptake inhibitor
Desvenlafaxine : Frequently Asked Questions
TLDR
Since February 2008 when desvenlafaxine first came to market, clinicians have wondered about the differences between this new antidepressant and venlafAXine extended release (ER).
Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence
TLDR
DVS is a useful addition to the options available for the treatment of MDD in light of the limited efficacy of currently available antidepressants and its simple metabolism, lower risk of drug–drug interactions and lack of need for extensive titration to achieve therapeutic efficacy.
Desvenlafaxine Succinate: A Newer Antidepressant for the Treatment of Depression and Somatic Symptoms
TLDR
Current evidence indicates that DVS has proven efficacy, acceptable safety and tolerability profiles, convenient dosing, and minimal impact on the cytochrome P450 enzyme system, which is a potential advantage over other selective serotonin noradrenaline reuptake inhibitors.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors
Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites.
TLDR
Novel findings, not widely described previously, suggest that many of the individual drugs studied in these experiments possess some structural characteristic that determines affinity for several G protein-coupled, but not muscarinic, receptors.
Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: Electrophysiological studies in the rat brain
TLDR
It is concluded that long-term CIT treatment enhances 5-HT neurotransmission by desensitizing both the somatodendritic and terminal 5- HT autoreceptors.
Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative.
Central pre- and postsynaptic 5-HT1A receptors in rats treated chronically with a novel antidepressant, cericlamine.
TLDR
The idea that postsynaptic and somatodendritic 5-HT1A receptors are differently regulated in the rat brain is supported, because only the latter receptors desensitized after a long-term blockade of serotonin reuptake by cericlamine is suggested.
Pharmacological heterogeneity of the cloned and native human dopamine transporter: disassociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding.
TLDR
Comparison of pharmacological homology, but not identity, with that of the cloned DA uptake process with the binding of [3H]WIN 35,428 and [3h]GBR 12,935 to COS-7 cells transiently expressing theCloned human DA transporter suggests two sites of the DA transporter are recognized, of which only one appears to represent the functional state of the protein.
Expression cloning of a cocaine-and antidepressant-sensitive human noradrenaline transporter
TLDR
A complementary DNA clone encoding a human noradrenaline transporter is isolated and the predicted protein sequence demonstrates significant amino-acid identity with the Na+/γ-aminobutyric acid transporter, thus identifying a new gene family for neurotransmitter transporter proteins.
SNRIs: The Pharmacology, Clinical Efficacy, and Tolerability in Comparison with Other Classes of Antidepressants
Abstract The class of serotonin and norepinephrine reuptake inhibitors (SNRIs) now comprises three medications: venlafaxine, milnacipran, and duloxetine. These drugs block the reuptake of both…
Early desensitization of somato-dendritic 5-HT1A autoreceptors in rats treated with fluoxetine or paroxetine
TLDR
Results show that adaptive desensitization of somatodendritic 5-HT1A autoreceptors within the dorsal raphe nucleus can already be detected after a 3-day treatment with selective serotonin reuptake inhibitors.
Cyclic AMP-independent Up-regulation of the Human Serotonin Transporter by Staurosporine in Choriocarcinoma Cells (*)
TLDR
It is concluded that staurosporine up-regulates the serotonin transport activity in JAR cells by increasing the steady state levels of the serotonin transporter mRNA and by the consequent increase in the transporter density in the plasma membrane and that the process involves a cAMP-independent signaling pathway.
...
1
2
3
4
...